Stocks Comparison
20/20 Biolabs vs UL Solutions: revenue, profit, margins and growth compared
20/20 Biolabs brought in $2M of revenue in fiscal 2025, UL Solutions $3.1B in fiscal 2025. Revenue changed by +16.7% at 20/20 Biolabs and +6.4% at UL Solutions on the year before, so 20/20 Biolabs grew faster. 20/20 Biolabs kept -182.8% of its revenue as net profit, UL Solutions 10.6%.
Side by side, latest fiscal year
| AIDX | ULS | |
|---|---|---|
| Fiscal year ended | FY2025 (December 31, 2025) | FY2025 (December 31, 2025) |
| Revenue | $2M | $3.1B |
| Revenue growth | +16.7% | +6.4% |
| Net income | -$3.7M | $325M |
| Net margin | -182.8% | 10.6% |
| Free cash flow | n/a | $403M |
| Free cash flow margin | n/a | 13.2% |
| Earnings per share (diluted) | -$0.76 | $1.60 |
| Cash | $1M | $295M |
| Debt | n/a | $491M |
| Price to earnings | n/a | 41.3 |
| Market value | $5.6M | $13.3B |
| Dividend yield | n/a | 0.79% |
| Rank by revenue in sector | #542 of 646 · Health care | #86 of 646 · Health care |
Over the years
Questions about 20/20 Biolabs and UL Solutions
Which is bigger by revenue, 20/20 Biolabs or UL Solutions?
UL Solutions is bigger by revenue: $3.1B in fiscal 2025, against $2M for 20/20 Biolabs in fiscal 2025.
Which keeps more of its revenue as profit, 20/20 Biolabs or UL Solutions?
20/20 Biolabs had a net margin of -182.8% in fiscal 2025; UL Solutions had 10.6% in fiscal 2025.
Which grew revenue faster, 20/20 Biolabs or UL Solutions?
In their latest fiscal years revenue changed by +16.7% at 20/20 Biolabs and +6.4% at UL Solutions.
Where do these numbers come from?
From the annual reports each company files with the SEC (10-K, or 20-F and 40-F for foreign companies), read from their XBRL data. Margins and growth are simple arithmetic on those figures. Nothing here is a recommendation.